A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
OncoMed Pharmaceuticals
Start Date
October 23, 2017
End Date
March 31, 2020
Administered By
Duke Cancer Institute
Awarded By
OncoMed Pharmaceuticals
Start Date
October 23, 2017
End Date
March 31, 2020